Annovis Bio Inc (ANVS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Annovis Bio Inc (ANVS) has a cash flow conversion efficiency ratio of -0.530x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-8.93 Million) by net assets ($16.85 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ANVS days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annovis Bio Inc - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Annovis Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Annovis Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Annovis Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fire & Gas Detection Technologies Ltd
TA:FGAS
|
-0.079x |
|
Chang Ho Fibre Corp
TW:1468
|
0.022x |
|
Meta Biomed Co. Ltd
KQ:059210
|
0.009x |
|
Transpaco Ltd
JSE:TPC
|
0.044x |
|
CBAK ENERGY TECH. NEW
F:B6JA
|
0.272x |
|
Byuksan Corp
KO:007210
|
0.012x |
|
ALBIS Leasing AG
XETRA:ALG
|
-0.083x |
|
Lion Finance Group PLC
LSE:BGEO
|
0.071x |
Annual Cash Flow Conversion Efficiency for Annovis Bio Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of Annovis Bio Inc from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see Annovis Bio Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $16.85 Million | $-25.62 Billion | -1520.344x | +35.37% |
| 2024-12-31 | $9.31 Million | $-21.89 Billion | -2352.325x | -45718.55% |
| 2023-12-31 | $-7.75 Million | $-39.97 Million | 5.157x | +943.59% |
| 2022-12-31 | $28.32 Million | $-17.31 Million | -0.611x | -197.82% |
| 2021-12-31 | $44.49 Million | $-9.13 Million | -0.205x | +61.02% |
| 2020-12-31 | $7.54 Million | $-3.97 Million | -0.527x | -1047.67% |
| 2019-12-31 | $-8.58 Million | $-476.54K | 0.056x | -24.46% |
| 2018-12-31 | $-7.59 Million | $-558.61K | 0.074x | -4.67% |
| 2017-12-31 | $-6.97 Million | $-537.48K | 0.077x | +114.53% |
| 2012-12-31 | $2.66 Million | $-1.41 Million | -0.531x | -145.69% |
| 2011-12-31 | $13.93 Million | $-3.01 Million | -0.216x | -100.99% |
| 2010-12-31 | $16.49 Million | $-1.77 Million | -0.108x | +59.22% |
| 2009-12-31 | $1.48 Million | $-389.23K | -0.264x | -- |
About Annovis Bio Inc
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury… Read more